Solvonis Therapeutics announced positive pharmacokinetic data for its SVN-002 program, repurposing J&J's esketamine for moderate to severe alcohol use disorder. The data show comparable drug exposure via sublingual and buccal delivery to the approved intranasal form, supporting FDA's 505(b)(2) pathway for faster development. This could accelerate the planned Phase 2b trial in the US, targeting a large market of 15 million affected adults. Next steps include FDA discussions on toxicology and submitting an IND application.
Ripple CEO Brad Garlinghouse remains bullish on bitcoin but criticized Michael Saylor's preferred-stock funding strategy used by Strategy to buy bitcoin. He called the approach "financial engineering" that distracted the market and pointed to the Str...
Major cryptocurrencies fell this week as investors favored AI-related stocks, with Dogecoin and Hyperliquid's HYPE dropping about 10%. Bitcoin was more resilient, dipping 5.3% but quickly rebounding from lows near $58,000 due to aggressive buying. Cr...
Mitsubishi Electric Corporation reported solid revenue and operating profit growth driven by investments in electrification, semiconductors, datacenters, and defense. The life segment, including air conditioning and building systems, remains the larg...
Waton Financial Limited has released MoTA Alpha, a major upgrade to its AI-powered investment platform that introduces an Agent Talents Market for third-party AI trading agents and improves multi-agent collaboration and user experience. This launch m...
Jito protocol has generated $1.75 billion in revenue, mainly from MEV and staking rewards, signaling strong economic activity on its network. User engagement is rising, with a significant increase in active addresses and a 90% jump in trading volume ...
